Valneva (VALN) news

French Pharma shares Genfit, Nanobiotix, Valneva down between 4.8% and 6.2%

On Monday, several French pharmaceutical stocks experienced declines, with Genfit S.A. (GNFT.PA), Nanobiotix, and Valneva all posting losses in the range of 4.8% to 6.2%. The drop comes amid broader market volatility and sector-specific pressures affecting biotech and pharmaceutical firms.…

Valneva SE shares down 3.9% after update on iXchIQ in the UK

Valneva: Decision based on safety data review

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) has taken a series of actions regarding its chikungunya vaccine, IXCHIQ®, based on a comprehensive review of safety data. In January 2026, the company voluntarily withdrew its U.S. Biologics License Application (BLA) and Investigational New Drug (IND)…

Valneva SE - MHRA decision not associated with newly identified safety signal

On February 13, 2026, Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced that the United Kingdom’s Commission on Human Medicines (CHM) has updated its recommendations for the use of Valneva’s single-dose chikungunya vaccine, IXCHIQ®. The updated Prescribing Information (PI) includes…

Valneva SE - MHRA revokes UK marketing authorization for ixchIQ

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) has recently experienced a regulatory setback in the United Kingdom, where the Medicines and Healthcare products Regulatory Agency (MHRA) has revoked the marketing authorization for its chikungunya vaccine, IXCHIQ®. This decision marks a significant…